Know Labs, Inc. to Host Review of First Quarter Fiscal Year 2025 Results on February 14, 2025
Know Labs (KNWN) has announced it will host a webcast on February 14, 2025, at 1:30 PM PT to discuss its first quarter fiscal year 2025 business updates and financial results for the period ended December 31, 2024. The company, which recently moved from NYSE American to OTC Markets, specializes in radio frequency dielectric spectroscopy (RFDS) for non-invasive medical diagnostic technology and has launched the Know Labs Technology Licensing (KTL) initiative.
The live audio webcast will be accessible to media and investors at https://ir.knowlabs.co starting at 1:15 PM PT, with a replay available afterward on the company's website.
Know Labs (KNWN) ha annunciato che ospiterà un webcast il 14 febbraio 2025, alle 13:30 PT, per discutere gli aggiornamenti aziendali e i risultati finanziari del primo trimestre dell'anno fiscale 2025, relativi al periodo conclusosi il 31 dicembre 2024. L'azienda, che di recente è passata da NYSE American a OTC Markets, si specializza nella spettroscopia dielettrica a radiofrequenza (RFDS) per la tecnologia diagnostica medica non invasiva e ha lanciato l'iniziativa Know Labs Technology Licensing (KTL).
Il webcast audio in diretta sarà accessibile ai media e agli investitori su https://ir.knowlabs.co a partire dalle 13:15 PT, con una registrazione disponibile successivamente sul sito web dell'azienda.
Know Labs (KNWN) ha anunciado que llevará a cabo un webcast el 14 de febrero de 2025, a la 1:30 PM PT, para discutir las actualizaciones empresariales y los resultados financieros del primer trimestre del año fiscal 2025, para el período que finalizó el 31 de diciembre de 2024. La empresa, que recientemente se trasladó de NYSE American a OTC Markets, se especializa en espectroscopia dielectrica de radiofrecuencia (RFDS) para tecnología de diagnóstico médico no invasivo y ha lanzado la iniciativa Know Labs Technology Licensing (KTL).
El webcast de audio en vivo estará accesible para los medios y los inversores en https://ir.knowlabs.co a partir de la 1:15 PM PT, con una repetición disponible después en el sitio web de la empresa.
Know Labs (KNWN)는 2025년 2월 14일 오후 1시 30분 PT에 2025 회계연도 1분 비즈니스 업데이트 및 2024년 12월 31일 종료된 기간의 재무 결과를 논의하기 위한 웹캐스트를 개최한다고 발표했습니다. 최근 NYSE American에서 OTC Markets로 이동한 이 회사는 비침습적 의료 진단 기술을 위한 라디오 주파수 유전체 분광학(RFDS)을 전문으로 하며 Know Labs 기술 라이센싱(KTL) 이니셔티브를 시작했습니다.
실시간 오디오 웹캐스트는 오후 1시 15분 PT부터 https://ir.knowlabs.co에서 미디어와 투자자에게 제공되며, 그 후 회사 웹사이트에서 재생할 수 있습니다.
Know Labs (KNWN) a annoncé qu'elle organisera un webcast le 14 février 2025 à 13h30 PT pour discuter des mises à jour commerciales et des résultats financiers du premier trimestre de l'exercice 2025, pour la période se terminant le 31 décembre 2024. L'entreprise, qui est récemment passée de NYSE American à OTC Markets, se spécialise dans la spectroscopie diélectrique par radiofréquence (RFDS) pour la technologie de diagnostic médical non invasive et a lancé l'initiative Know Labs Technology Licensing (KTL).
Le webcast audio en direct sera accessible aux médias et aux investisseurs sur https://ir.knowlabs.co à partir de 13h15 PT, avec une rediffusion disponible par la suite sur le site internet de l'entreprise.
Know Labs (KNWN) hat angekündigt, dass am 14. Februar 2025 um 13:30 Uhr PT ein Webcast stattfinden wird, um die Geschäftsinformationen und finanziellen Ergebnisse des ersten Quartals des Geschäftsjahres 2025 zu besprechen, die den Zeitraum bis zum 31. Dezember 2024 betreffen. Das Unternehmen, das kürzlich von der NYSE American zu den OTC Markets gewechselt ist, ist auf die dielektrische Spektroskopie im Radiofrequenzbereich (RFDS) für nicht-invasive medizinische Diagnosetechnologie spezialisiert und hat die Know Labs Technology Licensing (KTL) Initiative ins Leben gerufen.
Der Live-Audio-Webcast wird ab 13:15 Uhr PT für Medien und Investoren unter https://ir.knowlabs.co zugänglich sein, mit einer Wiederholung, die später auf der Unternehmenswebsite verfügbar ist.
- None.
- None.
Media and investors may access the live audio webcast at https://ir.knowlabs.co, beginning at 1:15 pm PT. The webcast will also be available for replay at the company’s website.
For more information on Know Labs’ diagnostic platform technology and its KTL initiative visit www.knowlabs.co.
About Know Labs Technology Licensing (KTL)
Know Labs Technology Licensing (KTL) is the dedicated licensing division of Know Labs, Inc. (OTC: KNWN), facilitating the global adoption of its patented Radio Frequency Dielectric Spectroscopy (RFDS) technology. With an extensive intellectual property portfolio, a structured licensing framework, and the proprietary e-RFDS© digital watermark, KTL enables corporations, universities, and research institutions to innovate with confidence while securing their developments from counterfeiting and unauthorized use.
About Know Labs, Inc.
Know Labs, Inc.’s platform technology uses radio frequency spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to be able to integrate into a variety of wearable, mobile or bench-top form factors. The Company believes that this patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. Among the Company’s first expected applications of the technology will be in a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. This product will require
Safe Harbor Statement
This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213197558/en/
Know Labs, Inc. Contact:
Investor Relations
T: 206-903-1351
ask@knowlabs.co
Source: Know Labs, Inc.
FAQ
When will Know Labs (KNWN) report Q1 FY2025 earnings?
What period does Know Labs' (KNWN) Q1 FY2025 earnings cover?
How can investors access Know Labs' (KNWN) Q1 FY2025 earnings webcast?
Why did Know Labs change from NYSE American (KNW) to OTC Markets (KNWN)?
